title: [Intratympanic Steroid Treatment for Severe Idiopathic Sudden Sensorineural Hearing Loss].
abstract: Systemic steroid therapy is the only standard drug therapy for severe idiopathic sudden sensorineural hearing loss (ISSHL). We have treated severe ISSHL patients with double combined therapy, intravenous steroids (IVS) and hyperbaric oxygen (HBO). In this study, we retrospectively examined the effects of intratympanic steroids (ITS) by adding it to the double combined therapy. The study subjects were 172 patients with severe ISSHL. Eighty patients (38 men and 42 women) were treated with the double combined IVS and HBO therapy between April, 2007 and July, 2010 (A group: Historical control arm). Ninety-two patients (51 men and 41 women) were treated with triple therapy, combined therapy with IVS and HBO plus ITS, between August, 2010 and October, 2013 (B group: Current protocol arm). Each group was divided into two subgroups; one with a pure-tone average (PTA) between 60 and 89 dB (A1 and B1) and the other with a PTA ≥ 90 dB. A 1, A2, B1, and B2 sub-groups had 56 (29 men, 27 women), 24 (9 men, 15 women), 64 (36 men, 28 women), and 28 (15 men, 13 women) patients, respectively. All patients were treated within 30 days from the onset. There was a statistically significant difference in hearing improvement between the A2 and B2 groups, whereas no significant difference was observed between the A1 and B1 groups. Furthermore, a significant difference was observed in all frequencies but 2 kHz between at the A2 group and B2 group, but not between the A1 and B1 groups. Multivariate logistic analysis revealed that the treatment method (double vs.. triple combined therapies) had the strongest impact on hearing improvement in the ISSHL patients with a PTA ≥ 90 dB. These results indicated that the B2 group demonstrated better hearing improvement than the A2 group and suggested that the addition of the ITS could be effective for profound ISSHL patients with a PTA ≥ 90 dB.
authors.forename: Toshiro
authors.initials: T
authors.lastname: Kawano
authors.forename: Masaki
authors.initials: M
authors.lastname: Matsuura
authors.forename: Keiko
authors.initials: K
authors.lastname: Yuda
authors.forename: Akemi
authors.initials: A
authors.lastname: Matsushima
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishitoya
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Ryo
authors.initials: R
authors.lastname: Ikoma
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Oridate
mesh_terms: D003907:Dexamethasone / Q000008:administration & dosage*; D004432:Ear, Middle; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D006801:Humans; D006931:Hyperbaric Oxygenation; D007267:Injections; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone